Stock Analysis

OncoSil Medical Full Year 2024 Earnings: AU$0.006 loss per share (vs AU$0.01 loss in FY 2023)

ASX:OSL
Source: Shutterstock

OncoSil Medical (ASX:OSL) Full Year 2024 Results

Key Financial Results

  • Net loss: AU$12.4m (loss widened by 9.1% from FY 2023).
  • AU$0.006 loss per share.
earnings-and-revenue-history
ASX:OSL Earnings and Revenue History September 2nd 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

OncoSil Medical shares are up 9.1% from a week ago.

Risk Analysis

Don't forget that there may still be risks. For instance, we've identified 5 warning signs for OncoSil Medical (3 shouldn't be ignored) you should be aware of.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.